PARI Pharma GmbH
🇩🇪Germany
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT01955980
- Locations
- 🇩🇪
UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz, Mainz, Germany
🇩🇪University Göttingen, Göttingen, Germany
🇩🇪University Munich, Munich, Germany
Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 72
- Registration Number
- NCT01953367
- Locations
- 🇩🇪
Inamed GmbH, Gauting, Germany
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 14
- Registration Number
- NCT01946711
- Locations
- 🇩🇪
HNO-Zentrum Mangfall-Inn, Rosenheim, Germany
🇩🇪University LMU Munich, Munich, Germany
🇩🇪University Göttingen, Göttingen, Germany
Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 14
- Registration Number
- NCT01439958
- Locations
- 🇩🇪
PARI Pharma GmbH, Graefelfing, Germany
L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Pari Pharma GmbH
- Target Recruit Count
- 130
- Registration Number
- NCT01334892
- Locations
- 🇩🇪
PARI Pharma GmbH, Graefelfing, Germany
© Copyright 2024. All Rights Reserved by MedPath